You are currently logged into
Hep Directory - My Account or Log Out
Hep Hep
  • Home
  • Basics
    • Basics
    • Introduction
    • Hepatitis A Virus
    • Hepatitis B Virus
    • Hepatitis C Virus
    • NAFLD/NASH
    • Alcoholic Liver Disease
    • Autoimmune Hepatitis
    • Primary Biliary Cholangitis
  • News
    • News
    • Newsfeed
    • Science News
    • Features
    • Conferences
    • Hep Stories
    • Hep Slideshows
    • Hep TV
    • By Author
    • RSS Links
  • Hot Topics
    • Hot Topics
    • Opioids
    • Hep A Outbreak Map
    • Newly Diagnosed
    • Help Paying for Treatment
    • Hepatitis C Testing
    • Hepatitis C Medications
    • Hepatitis B Testing
    • Hepatitis B Treatment
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • Bulk Subscriptions
    • Email Newsletter
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Community
    • Hep Stories
    • Hep Forums
    • Polls
    • Surveys
    • Ask Hep
    • Services Directory
    • Calendar
    • Bookstore
  • About Us
    • About Us
    • About Us
    • Masthead
    • Awards
    • Advertise
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#elafibranor

Tweet
  • Share

Lanifibranor Both Resolves NASH and Reduces Liver Fibrosis

The experimental therapy improved liver inflammation, fibrosis and metabolic parameters in six months.

What’s in the Pipeline for NAFLD and NASH Treatment?

Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.

Company Halts Leading NASH Drug but Another Shows Promise

Studies of PPAR agonists have yielded mixed results for people with fatty liver disease.

When Will We See Drug Treatments for NASH Fibrosis?

Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.

How is NAFLD/NASH treated?

International Liver Congress Roundup

A quick overview of our reporting on the 53rd International Liver Congress in Vienna

Elafibranor Shows Favorable Efficacy & Safety as PBC Treatment

Among those with primary biliary cholangitis, the investigational drug reduced alkaline phosphatase levels.

Generic image

NAFLD/NASH Medications

The NAFLD/NASH medications’ page includes specific information about each of the experimental dru...

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.